← All peptidesBlends
Retatrutide + Cagrilintide
Retatrutide + Cagrilintide ("Cagri-Reta")
Triple GLP-1/GIP/glucagon agonist paired with an amylin analog, researched as a four-pathway weight-management stack.
Typical dose
2–12 mg
Frequency
Once weekly (slow titration)
Half-life
—
Route
subcutaneous
Typical vial sizes
15 mg20 mg
Sample reconstitution
15 mg vial · 2 mL bac water · 7 mg dose
- Draw volume
- 0.933 mL
- Insulin units
- 93 units
- Concentration
- 7.50 mg/mL
- Doses per vial
- 2.1
Research notes
As sold: Retatrutide 12.5mg + Cagrilintide 2.5mg (also 10mg+5mg). Once-weekly with slow titration; not combined with other GLP-1 compounds.
Further reading
- Published research on Retatrutide + Cagrilintide (PubMed) →
- Clinical trials for Retatrutide + Cagrilintide (ClinicalTrials.gov) →
Links open live searches on authoritative databases — verify dosing and safety against primary sources.
Research use only.
Information on this page is a reference log compiled from public sources and is not medical advice. Consult a licensed physician before making any decisions about your health.